ATLANTA – (BUSINESS WIRE) – Mirion Technologies, Inc. (NYSE: MIR) (“Mirion”), today announced the rebranding of its Medical segment as the Mirion Medical group, comprised of the organization’s healthcare-focused Dosimetry Services, Sun Nuclear, CIRS, Biodex, and Capintec business units. The establishment of the Mirion Medical group reinforces the Mirion commitment to leveraging its expertise in ionizing radiation for healthcare applications.
“Our keystone focus on ionizing radiation has broad applicability in the healthcare field, and our solutions protect practitioners and improve outcomes for patients. Given the expanding scope of our work and commercial reach, it is natural to bring our healthcare businesses together under a unified banner,” notes Thomas Logan, CEO of Mirion Technologies and acting Mirion Medical President.
The Mirion investment in healthcare began in late 2003 with the Dosimetry Services division. Mirion Dosimetry Services betters the human condition by providing ongoing monitoring of radiation exposure for those who are occupationally exposed thereby removing the worry of radiation in their daily routines. The well-known Instadose®+ wireless dosimetry platform offers on-demand dose reads via mobile device or PC, automatic calendar-set dose reads, online badge reassignments, and high dose email alerts that keeps clinicians aware of their radiation risk with immediate dose results available at their fingertips.
Sun Nuclear, a key brand within the Mirion Medical group, offers Radiation Therapy and Diagnostic Imaging solutions and services that better the human condition by enhancing the checks and balances that keep cancer treatment safe, effective, and ever-improving. Through nearly 40 years of service, Sun Nuclear has innovated proven Quality Management solutions and is stronger than ever, with a continued commitment to easing technology adoption, optimizing Quality Management, and ensuring Patient Safety. Sun Nuclear has become strategically aligned with CIRS, leaders in tissue simulation technology, anthropomorphic phantoms, and comprehensive testing and verification solutions. With the introduction of the Mirion Medical brand, CIRS solutions will integrate into the Sun Nuclear brand.
In the Nuclear Medicine space, Biodex and Capintec teams now operate as one, under the Capintec name. Recognized as a leader in the development, manufacturing and marketing of state-of-the-art radiation measuring and monitoring instrumentation, Capintec seeks to better the human condition by protecting people from exposure during potentially life-saving diagnosis and therapy. From dose preparation to patient administration, Capintec nuclear medicine and molecular imaging solutions enhance safety and efficiency for technologists and physicists throughout the care continuum. The Biodex brand remains focused on Physical Medicine and Medical Imaging, providing science-based solutions for rehabilitation exercise and injury recovery, as well as advanced surgical and ultrasound tables to support a quality imaging experience for practitioners and patients.
“Mirion Medical represents the science of better. We’re committed to enhancing the delivery and ensuring the safety of healthcare treatments to truly better the human condition. For practitioners, our advanced technologies streamline workflows and reduce risk, while their patients benefit from a safer, more efficient healthcare experience. As a unified group, Mirion Medical innovates with complementary solutions in the fields of Medical Imaging, Radiation Therapy, Occupational Dosimetry, and Physical Medicine,” notes Mr. Logan.
The Mirion Medical group will take on a family brand identity that carries across all business units in the group. The new logos will feature the Mirion “M”, symbolizing the strength of this group as part of the Mirion Technologies family. This refreshed brand will become visible on all Mirion Medical group digital properties and at select upcoming events. Learn more about the Mirion Medical group at mirion.com/medical.
Mirion Technologies continues to be a leading provider of detection, measurement, analysis and monitoring solutions for the nuclear, defense, medical and research end markets. The establishment of Mirion Medical will not change how Mirion Technologies reports financial performance externally, or how the Industrial group operates.
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hope,” “intend,” “may,” “might,” “should,” “would,” “will,” “understand” and similar words are intended to identify forward looking statements. These forward-looking statements include but are not limited to, statements regarding the Mirion products, technology, and market positioning. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including those described under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” set forth in filings and reports we make from time to time with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.
Mirion Technologies is a leading provider of detection, measurement, analysis and monitoring solutions to the nuclear, defense, medical and research end markets. The organization aims to harness its unrivaled knowledge of ionizing radiation for the greater good of humanity. Headquartered in Atlanta (GA – USA), Mirion employs around 2,600 people and operates in 13 countries. For more information, and for the latest news and content from Mirion, visit Mirion.com.
Sun Nuclear, CIRS, Capintec, Biodex, and Instadose are registered trademarks or trademarks of Mirion Technologies, Inc. and/or its affiliates in the United States and/or other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005558/en/
For investor inquiries:
For media inquiries:
Source: Mirion Technologies, Inc.
Released July 5, 2022